ATG/GCSF therapy for new-onset T1D: mechanistic insights and longer term outcomes / Designer combination therapy: the rationale for B cell depletion and co-stimulation blockade

This abstract has open access
Abstract Summary
Submission ID :
IDS84277
Submission Type
Invited
Abstract Topics
Invited
Dr Alice Long
Benaroya Research Institute at Virginia Mason
Dr Michael Haller
University of Florida

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
IDS82290
Against the Motion: “Treat first, think later”
Invited
Invited
Professor Jay Skyler
IDS71294
An increasing case for virus in T1D
Invited
Invited
Dr Sarah Richardson
IDS71310
Answering simple questions with big data
Invited
Invited
Dr Richard Oram
IDS66287
Antigen-specific immunotherapy for prevention and treatment of autoimmune diseases
Invited
Invited
David Wraith
IDS63257
Beta-Cell Fragility As a Common Underlying Risk Factor in Type 1 and Type 2 Diabetes
Invited
Invited
Professor Adrian Liston
IDS44265
C-peptide Persistence in People with Type 1 Diabetes: Predictors and Consequences
Invited
Invited
Professor Helen Colhoun
IDS76279
CD8+ T-cell responses against conventional and neo-antigenic islet peptides
Invited
Invited
Dr Roberto Mallone
IDS20295
Clinical presentation of subjects in the TEDDY study
Invited
Invited
Dr Helena Elding Larsson
IDS82275
Designer combination therapy for T1D prevention: the rationale for B cell depletion and co-stimulatory blockade
Invited
Invited
Jane Buckner
13 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org